# Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis

> **NCT01510535** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 287 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** Placebo
- **DRUG:** Hyruan Plus
- **DRUG:** LBSA0103

## Key facts

- **NCT ID:** NCT01510535
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-10
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01510535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01510535, "Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01510535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*